Entering text into the input field will update the search result below

Cassava Sciences warns of potential clinical hold on simufilam in recent 10-K filing

Mar. 02, 2022 3:45 PM ETCassava Sciences, Inc. (SAVA)DNLI, QNCXBy: Jonathan Block, SA News Editor191 Comments

Headquarters of US Food and Drug Administration (FDA)

Grandbrothers/iStock Editorial via Getty Images

Cassava Sciences (SAVA +2.4%) has warned that it may face a clinical hold on its trials for simufilam after the U.S. FDA imposed them this year on two competitors that are also working on Alzheimer's

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.